Aulos Bioscience
Aulos Bioscience is a biotechnology company focused on revolutionizing cancer care through the development of a novel immune-activating antibody therapeutic, AU-007, designed to transform the treatment of solid tumors. Leveraging artificial intelligence and machine learning, the company computationally designs human monoclonal antibodies that precisely target IL-2 interactions to shift immune activity towards activation and away from suppression, aiming to overcome limitations and toxic side effects of existing IL-2 therapies. Their lead product candidate, AU-007, is in Phase 2 clinical trials for advanced solid tumors including melanoma and renal cell carcinoma, demonstrating a well-tolerated safety profile and promising anti-tumor activity. The company is co-founded by Biolojic Design and ATP, backed by $60 million in Series A funding, and is positioned as a changemaker in immuno-oncology with a unique approach to cancer immunotherapy.
Aulos Bioscience
Aulos Bioscience is a biotechnology company focused on revolutionizing cancer care through the development of a novel immune-activating antibody therapeutic, AU-007, designed to transform the treatment of solid tumors. Leveraging artificial intelligence and machine learning, the company computationally designs human monoclonal antibodies that precisely target IL-2 interactions to shift immune activity towards activation and away from suppression, aiming to overcome limitations and toxic side effects of existing IL-2 therapies. Their lead product candidate, AU-007, is in Phase 2 clinical trials for advanced solid tumors including melanoma and renal cell carcinoma, demonstrating a well-tolerated safety profile and promising anti-tumor activity. The company is co-founded by Biolojic Design and ATP, backed by $60 million in Series A funding, and is positioned as a changemaker in immuno-oncology with a unique approach to cancer immunotherapy.